Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oppenheimer

56.90
+1.071.92%
Post-market: 56.900.00000.00%19:32 EDT
Volume:70.72K
Turnover:4.01M
Market Cap:598.99M
PE:8.93
High:57.87
Open:56.03
Low:55.64
Close:55.83
Loading ...

Oppenheimer Adjusts Price Target on AT&T to $32 From $27, Keeps Outperform Rating

MT Newswires Live
·
01 Apr

Sensei Biotherapeutics (SNSE) Gets a Buy from Oppenheimer

TIPRANKS
·
30 Mar

Oppenheimer Sticks to Its Buy Rating for Durect (DRRX)

TIPRANKS
·
30 Mar

Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer

TIPRANKS
·
29 Mar

Lululemon Faces Choppy Macro Amid Internal Improvements, Oppenheimer Says

MT Newswires Live
·
28 Mar

Kyndryl's Weakness Provides Buying Opportunity, Oppenheimer Says

MT Newswires Live
·
28 Mar

Sensei Biotherapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
28 Mar

Oppenheimer Adjusts Price Target on Sensei Biotherapeutics to $4 From $3.50, Maintains Outperform Rating

MT Newswires Live
·
28 Mar

Oppenheimer Reaffirms Their Buy Rating on Regulus (RGLS)

TIPRANKS
·
28 Mar

Oppenheimer Remains a Buy on Alcon (ALC)

TIPRANKS
·
28 Mar

Oppenheimer Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
28 Mar

Pool (POOL) Receives a Buy from Oppenheimer

TIPRANKS
·
28 Mar

Oppenheimer Keeps Their Buy Rating on Kyndryl Holdings Incorporation (KD)

TIPRANKS
·
28 Mar

Oppenheimer Keeps Their Buy Rating on Braze (BRZE)

TIPRANKS
·
28 Mar

Aurora Innovation Initiated at Outperform by Oppenheimer

Dow Jones
·
27 Mar

Oppenheimer bullish on Aurora Innovation, initiates with an Outperform

TIPRANKS
·
27 Mar

Oppenheimer Initiates Coverage on Ouster With Outperform Rating, $16 Price Target

MT Newswires Live
·
27 Mar

Oppenheimer Initiates Aurora Innovation at Outperform With $15 Price Target

MT Newswires Live
·
27 Mar

Oppenheimer Remains a Buy on Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
27 Mar

Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer

Dow Jones
·
27 Mar